172 related articles for article (PubMed ID: 27314964)
1. Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study.
D'Amico E; Leone C; Zanghì A; Fermo SL; Patti F
J Neurol; 2016 Sep; 263(9):1802-9. PubMed ID: 27314964
[TBL] [Abstract][Full Text] [Related]
2. Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience.
D'Amico E; Patti F; Zanghì A; Lo Fermo S; Chisari CG; Zappia M
Expert Rev Clin Pharmacol; 2018 May; 11(5):531-536. PubMed ID: 29521113
[TBL] [Abstract][Full Text] [Related]
3. Assessing response to interferon-β in a multicenter dataset of patients with MS.
Sormani MP; Gasperini C; Romeo M; Rio J; Calabrese M; Cocco E; Enzingher C; Fazekas F; Filippi M; Gallo A; Kappos L; Marrosu MG; Martinelli V; Prosperini L; Rocca MA; Rovira A; Sprenger T; Stromillo ML; Tedeschi G; Tintorè M; Tortorella C; Trojano M; Montalban X; Pozzilli C; Comi G; De Stefano N;
Neurology; 2016 Jul; 87(2):134-40. PubMed ID: 27306626
[TBL] [Abstract][Full Text] [Related]
4. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
5. The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study.
Alroughani R; Ahmed SF; Behbehani R; Al-Hashel J
Pediatr Neurol; 2017 May; 70():56-60. PubMed ID: 28389054
[TBL] [Abstract][Full Text] [Related]
6. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
[TBL] [Abstract][Full Text] [Related]
7. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
[TBL] [Abstract][Full Text] [Related]
8. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
[TBL] [Abstract][Full Text] [Related]
10. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
[TBL] [Abstract][Full Text] [Related]
11. Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy.
Chalmer TA; Kalincik T; Laursen B; Sorensen PS; Magyari M;
J Neurol; 2019 Feb; 266(2):306-315. PubMed ID: 30515628
[TBL] [Abstract][Full Text] [Related]
12. Clinical and radiological consequences of delayed therapy escalation in patients with relapsing-remitting multiple sclerosis.
Popiel M; Bartosik-Psujek H
Neurol Neurochir Pol; 2024; 58(1):84-93. PubMed ID: 38112646
[TBL] [Abstract][Full Text] [Related]
13. Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis.
Rojas JI; Patrucco L; Miguez J; Besada C; Cristiano E
Neurol Res; 2014 Jul; 36(7):615-8. PubMed ID: 24620963
[TBL] [Abstract][Full Text] [Related]
14. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.
de Flon P; Gunnarsson M; Laurell K; Söderström L; Birgander R; Lindqvist T; Krauss W; Dring A; Bergman J; Sundström P; Svenningsson A
Neurology; 2016 Jul; 87(2):141-7. PubMed ID: 27316241
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
[TBL] [Abstract][Full Text] [Related]
16. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H
JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642
[TBL] [Abstract][Full Text] [Related]
17. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
[TBL] [Abstract][Full Text] [Related]
18. No evidence of disease activity status over 3 years in a real-world cohort of relapsing remitting MS patients in Germany.
Huhn K; Senger D; Utz KS; Schmidt M; Fröhlich K; Waschbisch A; Seifert F; Dörfler A; Lee DH; Linker RA
Mult Scler Relat Disord; 2019 Jan; 27():133-138. PubMed ID: 30384198
[TBL] [Abstract][Full Text] [Related]
19. Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.
Goodin DS; Reder AT; Traboulsee AL; Li DK; Langdon D; Cutter G; Cook S; O'Donnell T; Kremenchutzky M; Oger J; Koelbach R; Pohl C; Wicklein EM;
Mult Scler; 2019 May; 25(6):837-847. PubMed ID: 29761737
[TBL] [Abstract][Full Text] [Related]
20. Relapsing-remitting and primary progressive multiple sclerosis treated with ocrelizumab: A comparative study.
Rodriguez de Antonio LA; Cuberta-Gonzalez I; Garcia-Castañon I; Oreja-Guevara C
Mult Scler Relat Disord; 2023 Jan; 69():104441. PubMed ID: 36493559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]